Elizabeth Smyth

10PUBLICATIONS
14CO-AUTHORS
Predictive and prognostic markersTumour immunologyMolecular targetsCancer cell biologyCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Jun 24, 2024
Survival outcomes of Zo-NAnTAx: a five-year analysis of zoledronic acid added to a neoadjuvant regimen for HER2-positive breast cancer.

Bruno de Paula, Eliana Abdelhay, Carlos Augusto Moreira de Sousa

|May 16, 2024
Clinical considerations for estrogen receptor-negative/progesterone receptor-positive/HER2-negative (ER-PR+HER2-) breast cancer.

Bruno Henrique Rala de Paula, Susanne Crocamo, Jose Bines

|May 15, 2023
Nuclear and Cytoplasmic hTERT, Tumor-Infiltrating Lymphocytes, and Telomere Elongation Leukocytes Are Independent Factors in the Response to Neoadjuvant Treatment in HER2-Enriched Breast Cancer.

Lucas Delmonico, José Bines, Cristina Moreira do Nascimento

|Feb 08, 2023
Targeting Senescence as a Therapeutic Opportunity for Triple-Negative Breast Cancer.

Bruno de Paula, Rosalind Kieran, Samantha Shui Yuan Koh

|Dec 23, 2022
Translational Results of Zo-NAnTax: A Phase II Trial of Neoadjuvant Zoledronic Acid in HER2-Positive Breast Cancer.

Susanne Crocamo, Renata Binato, Everton Cruz Dos Santos

|Feb 05, 2022
Rethinking cancer clinical trials for COVID-19 and beyond.

Gary J Doherty, Mehmet Goksu, Bruno H R de Paula

Pageof 2

Frequent Collaborators

3 joint publications

Susanne Crocamo

2 joint publications

Rosalind Kieran

2 joint publications

Eliana Abdelhay

2 joint publications

Gary J Doherty